-- Sales of Sepra(R) products continued to be strong, rising 32 percent to
$30.6 million in the first quarter from $23.1 million in the same
quarter a year ago. The expanded U.S. sales force for Seprafilm(R)
adhesion barrier is reaching a broader range of physicians and helping
drive the product's growth in gynecologic and colorectal surgery.
Future growth of the product in C-section procedures and trauma
surgeries is expected.
-- First-quarter revenue for the Genetics business increased 12 percent to
$74.3 million from $66.2 million, fueled substantially by a higher
volume of reproductive diagnostic testing. The profitability of the
Genetics business is also increasing through improvements in operating
efficiencies, while Genzyme continues to invest in additional
information technology and infrastructure to strengthen the competitive
advantages the business has created. Genzyme Genetics recently
launched carrier and prenatal diagnostic testing for spinal muscular
atrophy, the most common inherited cause of infant mortality. These
tests are expected to support continued profitable growth in subsequent
-- Oncology revenue increased 29 percent in the first quarter to $29.0
million from $22.4 million. This growth primarily reflects the
addition of European sales of Clolar, which Genzyme began recording
following its acquisition of Bioenvision Inc. late last year. Genzyme
is working to introduce Clolar worldwide through its global commercial
and regulatory organization. Oncology revenue also reflects growing
first-line use of Campath(R) (alemtuzumab) in the treatment of patients
with B-cell chronic lymphocytic leukemia.
Late-State Development Programs
Genzyme continues to make strong prog
|SOURCE Genzyme Corp.|
Copyright©2008 PR Newswire.
All rights reserved